» Articles » PMID: 29877726

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis

Abstract

Rationale: Acquired resistance is an important driver of multidrug-resistant tuberculosis (TB), even with good treatment adherence. However, exactly what initiates the resistance and how it arises remain poorly understood.

Objectives: To identify the relationship between drug concentrations and drug susceptibility readouts (minimum inhibitory concentrations [MICs]) in the TB cavity.

Methods: We recruited patients with medically incurable TB who were undergoing therapeutic lung resection while on treatment with a cocktail of second-line anti-TB drugs. On the day of surgery, antibiotic concentrations were measured in the blood and at seven prespecified biopsy sites within each cavity. Mycobacterium tuberculosis was grown from each biopsy site, MICs of each drug identified, and whole-genome sequencing performed. Spearman correlation coefficients between drug concentration and MIC were calculated.

Measurements And Main Results: Fourteen patients treated for a median of 13 months (range, 5-31 mo) were recruited. MICs and drug resistance-associated single-nucleotide variants differed between the different geospatial locations within each cavity, and with pretreatment and serial sputum isolates, consistent with ongoing acquisition of resistance. However, pretreatment sputum MIC had an accuracy of only 49.48% in predicting cavitary MICs. There were large concentration-distance gradients for each antibiotic. The location-specific concentrations inversely correlated with MICs (P < 0.05) and therefore acquired resistance. Moreover, pharmacokinetic/pharmacodynamic exposures known to amplify drug-resistant subpopulations were encountered in all positions.

Conclusions: These data inform interventional strategies relevant to drug delivery, dosing, and diagnostics to prevent the development of acquired resistance. The role of high intracavitary penetration as a biomarker of antibiotic efficacy, when assessing new regimens, requires clarification.

Citing Articles

Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.

Vogensen V, Singh S, Allende C, Engelthaler D, Boorgula G, Thomas T Antimicrob Agents Chemother. 2025; 69(2):e0108424.

PMID: 39817762 PMC: 11823603. DOI: 10.1128/aac.01084-24.


Methods and Models for Studying in Respiratory Infections.

Franco C, Rezzani R Int J Mol Sci. 2025; 26(1.

PMID: 39795880 PMC: 11719571. DOI: 10.3390/ijms26010018.


Toward better cures for lung disease.

Dartois V, Dick T Clin Microbiol Rev. 2024; 37(4):e0008023.

PMID: 39360834 PMC: 11629636. DOI: 10.1128/cmr.00080-23.


Surveillance of fluoroquinolones resistance in rifampicin-susceptible tuberculosis in eastern China with whole-genome sequencing-based approach.

Che Y, Lu Y, Zhu Y, He T, Li X, Gao J Front Microbiol. 2024; 15:1413618.

PMID: 39050625 PMC: 11266052. DOI: 10.3389/fmicb.2024.1413618.


Triple-Antibiotic Combination Exerts Effective Activity against subsp. Biofilm and Airway Infection in an In Vivo Murine Model.

Offman E, Leestemaker-Palmer A, Fathi R, Keefe B, Bibliowicz A, Raday G Antibiotics (Basel). 2024; 13(6).

PMID: 38927142 PMC: 11200515. DOI: 10.3390/antibiotics13060475.


References
1.
Dheda K, Limberis J, Pietersen E, Phelan J, Esmail A, Lesosky M . Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. 2017; 5(4):269-281. DOI: 10.1016/S2213-2600(16)30433-7. View

2.
Pietersen E, Ignatius E, Streicher E, Mastrapa B, Padanilam X, Pooran A . Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014; 383(9924):1230-9. DOI: 10.1016/S0140-6736(13)62675-6. View

3.
Pasipanodya J, Gumbo T . A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis. 2013; 57(1):21-31. PMC: 3669525. DOI: 10.1093/cid/cit167. View

4.
Rockwood N, Pasipanodya J, Denti P, Sirgel F, Lesosky M, Gumbo T . Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clin Infect Dis. 2017; 64(10):1350-1359. PMC: 5411399. DOI: 10.1093/cid/cix158. View

5.
Pasipanodya J, McIlleron H, Burger A, Wash P, Smith P, Gumbo T . Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9):1464-73. PMC: 3789573. DOI: 10.1093/infdis/jit352. View